IPO boom times are back, with SpaceX and OpenAI on investors’ 2026 wish list. But be careful what you buy

The IPO market is re-accelerating in 2026 with far more listings than the 38 in 2022 and high-profile candidates such as SpaceX and OpenAI expected to debut, but historical data warn of significant downside: the 1999 class (476 IPOs) produced three-year returns of -48% from first-day closes and the 311 IPOs in 2021 returned -49% over three years. Research suggests revenue scale—firms with $100 million+ in annual sales—better predicts long-term success than profitability at IPO, while insiders selling after six months can clarify fundamentals; pre-IPO allocations are available but typically require large minimums (roughly $250,000). The piece advises patience—waiting until after the first six months or end of the IPO trading debut and performing traditional valuation work—rather than buying solely on first-day pops.

Analysis

Market structure: An expanding IPO supply benefits underwriters, late-stage VCs that can exit, and platforms handling private transactions (Rainmaker); it hurts retail buyers who face allocation frictions and small-cap liquidity as float increases. Expect pricing dispersion: incumbents (NVDA, MSFT, GOOGL) retain pricing power while many new entrants with < $100m sales will be competitively fragile, increasing idiosyncratic volatility over the next 6–36 months.

Risk assessment: Tail risks include a broad IPO cohort suffering multi-year drawdowns similar to 1999/2021 (three-year returns -40% to -50%), regulatory scrutiny of AI marketing claims, and concentrated lockup expiries ~6 months after listing causing forced selling. Near-term (days–weeks) volatility spikes around listings; medium-term (3–12 months) depends on lockups and macro rates; long-term (12–36 months) outcomes correlate with revenue scale (> $100m threshold materially improves odds).

Trade implications: Direct plays favor quality large-caps and hedged exposure to AI leaders (NVDA) while shorting aggregate new-issue exposure (Renaissance IPO ETF, ticker IPO). Use options to express view: buy 3–6 month put spreads on IPO ETF sized 1–2% of risk capital; avoid buying IPOs on open—prefer entry after 6 months or after lockup when fundamentals dominate price discovery.

Contrarian angles: Consensus lumps all IPOs as ‘risky’—that underweights select high-revenue (> $100m) IPOs and constrained-float winners (SpaceX/OpenAI) that can still outperform. The market may be underpricing the value of durable cash-flow companies listing in this window while overpricing headline-driven, low-sales offerings; regulatory moves to limit preferential allocations could flip first-day pops into retail-driven squeezes.

Key Decisions for Investors

• Establish a 2–3% long position in NVDA (ticker NVDA) over 6–18 months but hedge with a 6-month 10% OTM protective put (cost-limited) or finance by selling a 2–3% covered-call tranche to cap downside vs. capturing AI upside.
• Initiate a 1–2% notional short position in the Renaissance IPO ETF (ticker IPO) or buy a 3–6 month 10%/20% OTM put spread on IPO sized to 1–2% of portfolio risk; thesis: broad new-issue cohort underperforms if issuance >200 YTD or median IPO revenue < $100m.
• Implement a pair trade: long 2% MSFT (ticker MSFT) and short 2% IPO ETF (IPO) to capture quality growth vs. speculative supply; reweight after 6 months or upon lockup expiries.
• Allocate up to 0.5–1.0% to pre-IPO/private deals (SpaceX/OpenAI) only if minimums, valuation caps, and liquidity terms meet strict criteria (min $250k ticket, no secondary overhang for 12 months); otherwise avoid retail IPO allocations on listing day.
• Trigger-based risk control: if cumulative 2026 IPO count >200 by end-Q2 or average reported annual revenue for new issuers < $100m, reduce small-cap/IPO exposure by an additional 1–3% within 30 days and increase cash/short protection.